| Intravitreal bevacizumab for choroidal neovascularization secondary to Vogt-Koyanagi-Harada syndrome. | |
| | |
MedLine Citation:
|
PMID: 19184312 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Vogt-Koyanagi-Harada (VKH) syndrome is characterized by bilateral diffuse uveitis associated with auditory, neurological, and cutaneous signs and symptoms. VKH syndrome is a cell-mediated autoimmune disease against melanocytes. Choroidal neovascularization (CNV) occurs in 15% of VKH patients and is associated with poor visual prognosis. CASES: We report on two patients with VKH syndrome and CNV that were treated with intravitreal bevacizumab. OBSERVATIONS: One of the VKH patients also had an extrafoveal CNV membrane and underwent multiple intravitreal injections of bevacizumab in combination with laser photocoagulation, with subsequent improvement in visual acuity. The second had a subfoveal CNV that responded to a single intravitreal injection of bevacizumab. CONCLUSION: Intravitreal bevacizumab may be a useful drug to treat CNV in eyes with VKH syndrome. |
| | |
Authors:
|
Lihteh Wu; Teodoro Evans; Mario Saravia; Ariel Schlaen; Cristobal Couto |
Publication Detail:
|
Type: Case Reports; Journal Article Date: 2009-01-30 |
Journal Detail:
|
Title: Japanese journal of ophthalmology Volume: 53 ISSN: 1613-2246 ISO Abbreviation: Jpn. J. Ophthalmol. Publication Date: 2009 Jan |
Date Detail:
|
Created Date: 2009-02-02 Completed Date: 2009-05-15 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0044652 Medline TA: Jpn J Ophthalmol Country: Japan |
Other Details:
|
Languages: eng Pagination: 57-60 Citation Subset: IM |
Affiliation:
|
Instituto de Cirugía Ocular, San José, Costa Rica. LW65@cornell.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Angiogenesis Inhibitors / therapeutic use* Antibodies, Monoclonal / therapeutic use* Choroidal Neovascularization / drug therapy*, etiology Female Fluorescein Angiography Humans Injections Male Middle Aged Tomography, Optical Coherence Uveomeningoencephalitic Syndrome / complications* Vascular Endothelial Growth Factor A / antagonists & inhibitors Visual Acuity Vitreous Body |
| Chemical | |
Reg. No./Substance:
|
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/Vascular Endothelial Growth Factor A; 0/bevacizumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Severe choroidal ischemia following photodynamic therapy for pigment epithelial detachment and chron...
Next Document: Familial cerebral cavernous malformation: report of a further Italian family.